Wall Street Zen upgraded shares of TELA Bio (NASDAQ:TELA – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.
TELA has been the topic of a number of other research reports. UBS Group set a $2.00 price target on TELA Bio in a research note on Friday, September 25th. Weiss Ratings raised shares of TELA Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. Finally, Craig Hallum assumed coverage on shares of TELA Bio in a report on Friday, September 25th. They issued a “buy” rating and a $2.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $2.14.
Get Our Latest Analysis on TELA Bio
TELA Bio Trading Down 7.1%
TELA Bio (NASDAQ:TELA – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. TELA Bio had a negative return on equity of 1,320.81% and a negative net margin of 53.57%. The firm had revenue of $18.96 million for the quarter, compared to analyst estimates of $20.00 million. On average, sell-side analysts anticipate that TELA Bio will post -0.70 earnings per share for the current year.
Insider Transactions at TELA Bio
In related news, Director Joseph Capper acquired 25,000 shares of the business’s stock in a transaction on Thursday, September 17th. The stock was purchased at an average cost of $1.22 per share, for a total transaction of $30,500.00. Following the completion of the transaction, the director directly owned 179,827 shares of the company’s stock, valued at approximately $219,388.94. The trade was a 16.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have purchased 100,000 shares of company stock worth $109,000 in the last three months. Company insiders own 1.10% of the company’s stock.
Hedge Funds Weigh In On TELA Bio
Several institutional investors and hedge funds have recently made changes to their positions in TELA. Rollins Financial Advisors LLC bought a new position in shares of TELA Bio during the third quarter worth approximately $33,000. StoneX Group Inc. bought a new stake in TELA Bio in the 3rd quarter valued at $34,000. Wavvest Wealth LLC bought a new stake in TELA Bio in the 3rd quarter valued at $96,000. WealthTrust Axiom LLC boosted its stake in TELA Bio by 20.2% in the 3rd quarter. WealthTrust Axiom LLC now owns 550,128 shares of the company’s stock valued at $633,000 after purchasing an additional 92,394 shares during the period. Finally, UP Strategic Wealth Investment Advisors LLC acquired a new position in TELA Bio in the 2nd quarter valued at $91,000. Institutional investors and hedge funds own 94.35% of the company’s stock.
TELA Bio Company Profile
TELA Bio is a medical technology company that develops and markets products for soft-tissue reconstruction. Its portfolio includes OviTex Reinforced Tissue Matrices, which combine biologic materials derived from ovine (sheep) tissue with polymer reinforcement. The products are designed to support tissue repair and are used in procedures including hernia and abdominal wall reconstruction. The company also offers products for plastic and reconstructive surgery, including OviTex PRS, and other solutions for soft-tissue repair.
Further Reading
- Five stocks we like better than TELA Bio
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.
